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PREVALENCE OF AVOIDANT/RESTRICTIVE  
FOOD INTAKE DISORDER AND ASSOCIATION WITH NUTRITION STATUS IN 
PATIENTS WITH INFLAMMATORY BOWEL DISEASES 
 
by Emily R. Yelencich 
There is a large body of research on the relationship between inflammatory bowel 
disease (IBD) and diet; however, few conclusive, generalizable recommendations have 
been determined. Regardless, IBD patients often alter their normal dietary intake, which 
is concerning considering the prevalence of malnutrition in the IBD population. 
Avoidant/restrictive food intake disorder (ARFID) is a feeding disorder that was recently 
added to the Diagnostic and Statistical Manual of Mental Disorders and its prevalence 
and impact on the nutritional status of IBD patients has not previously been described. In 
this study ARFID risk was measured using the Nine-Item ARFID Screen and in the 161 
outpatient, adult IBD participants 17% were at ARFID risk. Participants who avoid food, 
regardless of disease status, had significantly higher ARFID risk scores than those who 
do not avoid food. Participants who reported symptoms of diarrhea, pain, no appetite, and 
fullness were significantly more likely to be at ARFID risk than those who did not. 
Nutritional risk was measured using the Patient Generated-Subjective Global Assessment 
(PG-SGA). ARFID risk score and nutritional risk score were positively correlated (rs= 
0.196, P = 0.024), indicating that participants with a higher ARFID risk score were also 
at risk for malnutrition. These results demonstrate that IBD patients should be regularly 
screened for malnutrition and food avoidance, endorsing the critical role of a registered 
dietitian as part of the IBD patient care team.  
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Inflammatory bowel disease (IBD) is a chronic inflammatory illness that 
encompasses two diagnoses: Crohn’s disease (CD) and ulcerative colitis (UC). There is 
no cure for CD or UC and the best outcome for people with IBD is to remain in 
remission, while managing uncomfortable and disruptive functional gastrointestinal 
symptoms. Disease etiology and status in IBD is multifactorial and influenced by a 
combination of genetic and environmental factors (Nahikian-Nelms, 2006). One of the 
primary environmental factors that people with IBD can manipulate is diet. While many 
diets have been suggested for the management of functional gastrointestinal symptoms 
and disease management, there is a lack of easily accessible, conclusive, dietary 
recommendations on which patients can make dietary choices. Even so, it is well 
documented that people with IBD believe that their dietary choices influence their disease 
status (Jowett et al., 2004; Limdi, Aggarwal, and McLaughlin, 2016; Zallot et al., 2013). 
This leads patients with IBD to alter their dietary intake based on advice from the internet 
(Marsh et al., 2019; Tinsley et al., 2016; Zallot et al., 2013) and under the direction of 
clinical providers who do not always feel they have sufficient nutrition care resources or 
adequate nutrition training (Raman, & Coderre, 2009; Scolapio, Buchman, & Floch, 
2008; Tinsley et al., 2016). When this independent, unsupervised approach at dietary 
intake is combined with confusion about what defines the most appropriate diet for IBD, 
patients run the risk of developing restrictive eating behaviors that can result in deficient 
	 2 
nutritional intake, increasing their risk for malnutrition (Vidarsdottir, Johannsdottir, 
Thorsdottir, Bjornsson, & Ramel, 2016). This review will present research about diet and 
IBD onset and disease course, specific diets for IBD treatment and management, and the 
dietary beliefs, disordered eating behaviors and eating disorders, and nutritional risks of 
people with IBD.  
Inflammatory Bowel Disease Etiology 
In both CD and UC, the delicate homeostasis of the gastrointestinal immune system is 
compromised, leading to varying degrees of intestinal inflammation (Kim, & Cheon, 
2017). Due to the multifactorial nature of IBD, the exact etiology has not been identified; 
however, according to the Crohn’s and Colitis Foundation of America (2014), the 
predominant theory is that a disturbance in the normal immune system response leads to a 
dysfunctional immune system attack on the healthy microbiota in the intestine, leading to 
chronic intestinal inflammation. While it is difficult to determine the exact combination 
of factors that lead to this abnormal immune response, it is clear that people with a 
genetic predisposition are more susceptible to developing IBD in response to a 
combination of environmental factors. Environmental factors include diet, smoking, 
antibiotic treatment, geography, and stress (Ananthakrishnan, 2015). Research has shown 
that dietary factors can contribute to the development of IBD by altering the composition 
of the gut microbiota and by directly regulating gastrointestinal immune cells (Sugihara, 
Morhardt, & Kamada, 2019). These disruptions can lead to an abnormal inflammatory 
response, resulting in the development of CD or UC. Once the homeostasis of the 
gastrointestinal immune cells and microbiota is compromised, dietary factors can further 
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exacerbate or ameliorate the disease (Sugihara, Morhardt, & Kamada, 2019). The 
complexity of the relationship between dietary intake, microbiota, and inflammatory 
response makes studying the effects of diet on IBD complicated and important. 
Impact of Diet on IBD 
Diet and IBD onset. Most research on the relationship between diet and IBD has 
focused on disease onset. In a literature review by Spooren et al. (2013), researchers 
found 36 studies investigating diet and IBD onset, compared to six studies investigating 
diet and disease relapse. Conclusions from these studies vary; however, they highlight 
dietary factors that are associated with higher risk of developing IBD such as total fat, 
protein, and sugar, and they suggest that a high intake of fruits and vegetables may be 
protective against disease onset.  
One area of research about dietary intake prior to disease onset is lipid intake. In Reif 
et al. (1997), researchers calculated the relative risk of developing UC between the 
highest and lowest tertiles of poly-unsaturated fatty acids (PUFA), mono-unsaturated 
fatty acids (MUFA), and cholesterol intake. They found that people in the highest tertile 
of PUFA, MUFA, and cholesterol intake were 6.54, 3.66, and 5.57 times more likely to 
develop UC, respectively, than those in the lowest tertile. In Geerling et al. (2000), 
researchers confirmed Reif et al. (1997), finding that people in the highest tertile of 
PUFA and MUFA intake were 5.1 and 33.9 times more likely to develop UC, 
respectively, compared to those in the lowest tertile intake.  
There are many types of PUFA and John et al. (2010) focused on the association of 
two omega-3 PUFAs with disease onset: eicosapentaenoic acid (EPA) and 
	 4 
docosahexaenoic acid (DHA). Researchers found that people in the highest tertile of 
DHA intake were 79% less likely to develop UC compared to people in the lowest tertile. 
The odds ratio (OR) trend across tertiles was 0.47 (95% confidence interval (CI): 0.25–
0.89).  Researchers did not find a significantly protective effect of intakes in the highest 
tertiles of EPA or total omega-3 PUFA compared to intakes in the lowest tertiles. In a 
large scale, prospective cohort study that investigated fatty acid intake and IBD onset, 
Chan et al. (2014) also found a protective effect of DHA on the onset of CD, with a 94% 
reduction in the odds of developing incident CD for participants with the highest quintile 
of DHA intake and a significant OR trend across quintiles.  
Inversely, research has shown high omega-6 PUFA intake increases risk of 
developing both UC and CD (Amre et al., 2007; Tjonneland et al., 2009). Amre et al. 
(2007) found that children with a high omega-6 intake were nearly twice as likely to 
develop CD compared to healthy controls and Tjonneland et al. (2009) found that adults 
with the highest intake of the omega-6 fatty acid, linoleic acid, were nearly two and a half 
times more likely to develop UC. Multiple studies investigating the association between 
high total omega-6 intake and the onset of UC have demonstrated a trend toward higher 
risk; however, they have not reached statistical significance (Geerling et al., 2000; 
Sakamoto et al., 2005). 
Other studies that looked at dietary intake and the risk of developing IBD did not find 
significant associations between IBD onset and lipid intake (Jantchou, Morois, Clavel-
Chapelon, Boutron-Ruault, & Caronnel, 2010; Tragnone et al., 1995). These studies did 
find significant results for different nutrients. Jantchou et al. (2010) found that individuals 
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in the highest tertile for protein intake were 3.31 times more likely to develop IBD than 
those in the lowest. Tragnone et al. (1995) also saw a significant difference in total 
protein intake between people with IBD (91.3 standard deviation (SD) ± 18.6g) and 
healthy controls (80.9 SD ± 15.5g) and Opstelten et al. (2018) concluded that IBD 
patients consume an additional 3.5g of protein per day compared to healthy controls. 
Conversely, a number of other studies did not find significant differences or increased 
risk ratios between protein intake and disease onset (Geerling et al., 2000; Hart et al., 
2008; Sakamoto et al, 2005; Reif et al., 1997). 
Tragnone et al. (1995) and Opstelten et al. (2018) also found a positive association 
between IBD onset and the consumption of carbohydrates. Tragnone et al. (1995) found 
that people with IBD consumed significantly more total carbohydrates (331.3 SD ± 
89.3g), starches (202.6 SD ± 70.3g), and refined sugar (101.43 SD ± 37.08g) compared to 
healthy controls (232.5 SD ± 67.9g, 126.8 SD ± 42.4g, 83.5 SD ± 30.6g, respectively). 
Again, Opstelten et al. (2018) confirmed these findings, demonstrating that IBD patients 
consumed an average of 10.1g of additional carbohydrates per day compared to healthy 
controls. Other studies did not find significant differences or increased risk between 
carbohydrate intake and disease onset (Geerling et al., 2000; Hart et al., 2008; Jantchou et 
al., 2010; Sakamoto et al, 2005).  
Spooren et al. (2013) reviewed 32 studies investigating the effects of fruit and 
vegetable intake on IBD onset and found that over half did not find any significant 
associations; however, 13 studies did show a protective effect. Compared to people with 
a low intake of fruits and vegetables, Porro and Panza (1985) found that people with a 
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high intake of fruits and vegetables had a relative risk of developing UC between 0.30 
and 0.38. Similarly, Hansen et al. (2011) found that people who ate fruits daily were 61% 
less likely to develop CD and 44% less likely to develop UC. People who ate vegetables 
daily were 59% less likely to develop CD and 49% (95% CI: 0.31–0.84) less likely to 
develop UC. Unlike the dietary constituents previously reviewed, none of the articles 
reviewed by Spooren et al. (2013) showed an increased risk of developing IBD for people 
with a high intake of fruits and vegetables. 
These studies demonstrate the inconsistent evidence regarding the role of dietary 
factors in the onset of IBD. The inconsistent results could be related to methodological 
differences and the inaccuracy inherent in collecting dietary data. Methodologically, 
studies used a variety of instruments for collecting dietary intake, from food frequency 
questionnaires (FFQ), to 7-day food diaries. Each instrument has strengths and 
limitations, and each will lead to different conclusions (Thompson et al., 2015). Another 
methodological problem is that most studies use FFQs to measure the dietary intake of 
participants; however, absolute intake cannot be reliably measured through this 
instrumentation. Instead, dietary intake is ranked; however, there are no set standards, 
across studies, for what constitutes a high, medium, or low intake. This complicates the 
interpretation of how dietary factors impact risk of IBD onset and relapse. These studies 
highlight the inconsistent results that contribute to confusion in the field for both medical 
practitioners as well as IBD patients. 
Diet and IBD relapse. Similarly, there are varying results in the limited research on 
how diet impacts IBD disease course. In a cross-sectional study, Tasson et al. (2017) 
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examined the association between the current diet and disease status of participants. They 
found that participants with the highest intake of legumes and potatoes had a 79% lower 
risk of active disease. This study did not account for disease course over time, or any 
changes in dietary intake in response to disease course.  
In a prospective study, Opstelten et al. (2018) followed IBD participants for two 
years, monitoring them for disease relapse. Thirty percent of participants relapsed, and 
researchers associated ‘high’ or ‘low’ intake of macronutrients with relapse. They found 
that participants who consumed a diet high in total fat, saturated fat, and mono-
unsaturated fat were 37%, 77%, and 63% less likely to relapse, respectively. Conversely, 
participants with a high intake of dietary fiber were 3.65 times more likely to relapse. 
Jowett et al. (2004) followed UC patients for one year to observe dietary intake and 
relapse. They found that individuals in the highest tertile of all meat (excluding fish) 
intake were 3.74 times more likely to relapse compared to those in the lowest tertile. 
Individuals with a high consumption of red and processed meats were 6.88 times more 
likely to relapse compared to those in the lowest tertile. Jowett et al. (2004) did not find 
any significant differences between fat or carbohydrate intake and risk of relapse.  
These studies each identify a different macronutrient that may be associated with a 
higher risk of relapse. The inconsistent results may be due to similar methodological 
differences in the research about diet and IBD onset. These findings confirm that the 
complicated relationship between diet and IBD extends from disease onset throughout 
disease course.  
 
	 8 
Dietary Effects of Specific Diets on IBD 
Even with varying results about the impact of diet on disease onset and relapse, there 
is a collection of research investigating the impact of IBD specific diets on disease course 
and symptom management. In their guidelines for clinical nutrition in IBD, the European 
Society for Clinical Nutrition and Metabolism (ESPEN) delivered a strong consensus that 
“there is no ‘IBD diet’ that can be recommended to promote remission in patients with 
active disease” (Forbes et al., 2017). They also agreed that research does not support a 
generalizable, optimal diet for maintaining disease remission (Forbes et al., 2017). 
Additionally, in a review for the Academy of Nutrition and Dietetics Evidence Analysis 
Library, weak/limited evidence was found to support the efficacy of medical nutrition 
therapy for gastrointestinal disorders (excluding celiac disease); however, only one, poor 
quality review article met the inclusion criteria for the review. In the absence of 
evidenced based medical nutrition therapy guidelines, the Academy of Nutrition and 
Dietetics’ Nutrition Care Manual offers some guidance to practicing dietitians. It advises 
that the primary goals of nutrition intervention should be to identify impediments to 
adequate oral intake, correct or compensate for malabsorption, and meet increased 
nutritional requirements while correcting for nutritional deficiencies and losses. When a 
patient is in an acutely active disease phase, their nutrient absorption, transit time, and/or 
ability to consume food orally may be impaired. If a patient cannot meet their needs 
orally, enteral or parenteral nutrition may be necessary; however, this treatment is not 
intended to induce remission in adult IBD patients (Eiden et al., 2003; Forbes et al., 
2017). A patient in active disease who can consume food orally, should eat small, 
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frequent meals that are low in fat and fiber and high in protein and calories, ultimately 
aiming for a normal diet (Eiden et al., 2003). In disease remission, the Nutrition Care 
Manual recommends adjusting the diet of a patient based on their changing 
gastrointestinal function, prioritizing energy and protein intake to support weight 
management and nutrient intake. While the Nutrition Care Manual does not provide 
specific dietary recommendations on how to manage functional gastrointestinal 
symptoms or on how to reduce the risk of relapse, researchers continue to explore how 
adherence to particular diets such as the Specific Carbohydrate Diet, the low fermentable 
oligo-, di-, mono-saccharides and polyols diet, and the anti-inflammatory diet impact 
disease course and symptom presentation.  
IBD and the Specific Carbohydrate Diet. The Specific Carbohydrate Diet (SCD) 
aims to induce and maintain drug-free remission in IBD patients by eliminating the 
consumption of disaccharides and most polysaccharides. The proposed mechanism for 
the SCD is that people with IBD produce too much intestinal mucus, inhibiting 
disaccharidases in the luminal brush border. This prevents the proper digestion and 
absorption of disaccharides, leading to intestinal injury and functional gastrointestinal 
symptoms (Gottschall, 1994). While the diet and pathway are not endorsed by any 
professional dietetic organizations, there is evidence that the SCD impacts the 
microbiome and can exacerbate or diminish inflammation (Kakodkar, Mikolaitis, Engen, 
& Mutlu, 2013). 
In studies on the SCD in the adult IBD population, results have shown a positive 
effect. In a self-reported survey of 50 adults who self-treated their IBD with the SCD, 
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66% experienced clinical remission after a mean diet duration of 9.9 months. Several 
subjects also stopped corticosteroid therapy while on the SCD (Kakodar, Farooqui, 
Mikolaitis, & Mutlu, 2015). In another study, 417 IBD patients in a SCD support group 
participated in a self-reported survey. After two months of following the SCD 33% of 
participants reported remission, and after both six and twelve months, 42% reported 
remission. Of the participants who reported reaching remission, 13% reported that they 
experienced remission in less than two weeks, 17% reported that it took from two weeks 
to a month, 36% reported that it took from one to three months, and 34% reported that it 
took more than three months. For individuals who reported reaching remission, 47% 
reported an improvement in abnormal laboratory values (Suskind et al., 2016). While 
these studies highlight and confirm the positive perception of the SCD, there have not 
been rigorous, placebo-controlled studies to verify the efficacy of the diet. 
IBD and the anti-inflammatory diet. The anti-inflammatory diet (IBD-AID) is 
another IBD specific diet that is based on the tenets of the SCD and is not endorsed by 
any professional dietetic organizations. The IBD-AID upholds the theory that consuming 
lactose and refined or processed complex carbohydrates can lead to gastrointestinal injury 
and inflammation. It also places an additional emphasis on the importance of pre- and 
probiotics in gut health, balancing the composition of fatty acid intake, and ensuring 
sufficient micronutrient intake based on individual assessment. It also suggests altering 
food texture to reduce intact fiber and improve absorption.  
The proper implementation of and adherence to this diet is difficult due to its multi-
component, individualized nature. This barrier was emphasized by the high withdrawal 
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rate in a study from the researchers who developed the IBD-AID (Olendzki et al., 2014). 
Initially dietitians met with 37 IBD patients about the IBD-AID; however, only 11 
participants were included in the analysis due to withdrawal (13 participants) or 
incomplete data (13 participants). The 11 participants (8 CD, 3 UC) who met the 
inclusion criteria followed the IBD-AID for at least four weeks, recording their dietary 
intake and symptoms. Participants with CD had a mean reduction of their Harvey 
Bradshaw Index (HBI) score from 11 (range: 0–20) to 1.5 (range: 0–3), indicating that all 
participants reached disease remission (HBI ≤ 4). Participants with UC had a mean 
reduction of their Modified Truelove and Witts Severity Index (MTLWSI) score from 7 
(range: 6–8) to 0, indicating that all participants reached disease remission (MTLWSI ≤ 
2). While these results suggest a promising effect of the IBD-AID, they should be 
interpreted with skepticism due to the small sample size and lack of control/placebo 
groups. Furthermore, the association of the researchers with and investment in the diet 
may have impacted results by influencing the recruitment process or the level of dietary 
guidance that participants received. More research, from unaffiliated groups is required 
before the diet is recommended and implemented.  
IBD and the low fermentable oligo-, di-, mono-saccharides and polyols diet. 
While the SCD and IBD-AID eliminate complex carbohydrates, the low fermentable 
oligo-, di-, mono-saccharides and polyols diet (LFD) takes the opposite approach, 
restricting specific simple carbohydrates. Also, unlike the SCD and IBD-AID, the LFD is 
not intended to be followed, comprehensively, in the long-term. Instead, it is intended to 
be an elimination diet with a reintroduction period aimed at identifying dietary triggers 
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unique to each individual. This diet significantly reduces or eliminates the intake of short-
chain carbohydrates, fructose, lactose, fructans, polyols, and galacto-oligosaccharides. 
These carbohydrates are poorly absorbed and highly fermentable, leading to functional 
gastrointestinal symptoms like diarrhea, gas, and bloating (Gibson, & Shepherd, 2005). 
Many studies have shown that the LFD successfully manages functional gastrointestinal 
symptoms in people with irritable bowel syndrome (Böhn et al., 2015; de Roest et al., 
2013; Staudacher, Whelan, Irving, & Lomer, 2017). In an observational study by de 
Roest et al. (2013), participants with irritable bowel syndrome responded to a symptom 
severity survey that used a 7-point Likert scale to assess the impact of the LFD on 
multiple functional gastrointestinal symptoms. Researchers found that adherence to the 
LFD was associated with the significant improvement of bloating, abdominal pain, gas, 
and diarrhea.  
Because many people with IBD have functional gastrointestinal symptoms, the LFD 
has also been tested on and prescribed to people with IBD. In an observational study 
performed on an IBD cohort, 56% of participants on the LFD reported improvement in 
their overall functional gastrointestinal symptoms, indicating that the LFD can be a useful 
symptom management tool for people with IBD (Gearry et al. 2009). In another 
prospective, intervention study, Pedersen et al. (2017) randomly assigned people with 
IBD to the LFD or to a normal diet for six weeks, collecting irritable bowel syndrome 
symptom severity surveys at baseline and after the intervention. Researchers found that 
after six weeks, the LFD group showed a significantly lower median irritable bowel 
syndrome symptom severity score (median: 115) than the normal group (median: 170). 
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When analyzed by disease type, researchers saw a significant irritable bowel syndrome 
symptom severity score improvement in participants with CD on the LFD (median: 58) 
compared to participants with CD on the normal diet (median: 220). The irritable bowel 
syndrome symptom severity score did not significantly improve for participants with UC 
on the LFD (median: 120) compared to participants with UC on the normal diet (median: 
141).  
While symptom management is important for patients with IBD it does not 
necessarily reflect the disease status of a patient or the ability of a diet to control disease 
maintenance or relapse. While Pedersen et al. (2017) did not see a significant 
improvement of irritable bowel syndrome symptoms in UC participants; the Simple 
Clinical Colitis Index, used to measure UC disease activity, significantly decreased in the 
LFD group (baseline: 3, week 6: 1). In the normal diet group, the UC disease activity did 
not change (baseline: 2, week 6: 2). Crohn’s disease participants on the LFD did not 
experience a significant reduction in their HBI disease activity score. This indicates that 
the LFD may be more effective in disease management for IBD patients with UC than 
CD. One factor that may have influenced these results was that there were fewer 
participants with CD than UC and it is possible that there were not enough CD 
participants to achieve sufficient power and observe a significant improvement in disease 
activity. While research on the LFD demonstrates conditionally positive results for 
symptom management and disease activity management, it is a very restrictive diet that 
merits further research into the long-term effects on nutrition status in people with IBD.  
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Dietary Beliefs and Eating Behaviors of People with IBD 
Based on the complicated nature of the previously reviewed diets and the inconsistent 
methodologies and conclusions, it is not surprising that the IBD patient population is 
uncertain about the best diet to follow for their disease. Even with this confusion, it has 
been shown that IBD patients do believe that diet plays a role in their disease course and 
that they hold strong dietary beliefs.   
In a study performed by Limdi et al. (2016) on 400 IBD patients, researchers found 
that 48% of participants believed that diet could be an initiating factor for IBD and 57% 
of participants identified diet as a potential cause of relapse. In a similar study, Zallot et 
al. (2013) found that 57.8% of IBD participants believed that food could lead to IBD 
relapse; however, only 15.6% of participants thought that food could initiate IBD. 
Similarly, Jowett et al. (2004) found that 68% of UC participants believed that their 
dietary choices impacted their disease and 39% believed that specific foods lead to 
relapse. While a higher percentage of IBD patients hold beliefs about how food 
negatively impacts their disease status, Limdi et al. (2016) also found that 16% of IBD 
patients thought that specific foods could improve their IBD symptoms. 
Jowett et al. (2004) found that the food groups dairy, fruits, and vegetables were most 
commonly avoided due to the perception that they had a negative impact on disease 
status. The food groups that were most commonly reported to be the most beneficial to 
the disease status of participants were fruits, vegetables, breads, cereals, and potatoes. 
Participants in Cohen et al. (2013) reported that yogurt and rice improved IBD symptoms 
and identified 18 foods or food groups that exacerbate symptoms. Some of the most 
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commonly reported, detrimental foods were non-leafy and leafy vegetables, spicy foods, 
nuts, fried foods, milk, and red meat.  
While IBD patients hold many beliefs about how food impacts their disease course, 
this does not necessarily mean that they alter their diets based on those beliefs; however, 
many studies have investigated eating behavior in the IBD population and have shown 
that between 49-90% of IBD patients do avoid specific foods (Bergeron, Bouin, D’Aoust, 
Lemoyne, & Presse, 2018; Holt, Strauss, & Moore, 2017; Jowett et al., 2004; Marsh et 
al., 2019; Walton, & Alaunyte, 2014; Vidarsdottir et al., 2016). Similarly, Jowett et al. 
(2004) found that 22% of participants ate more of the foods they perceived to help their 
disease. 
Cohen et al. (2013) also investigated the connection between food beliefs and eating 
behaviors by comparing food frequency questionnaires of IBD participants to their food 
beliefs. Results showed that participants do alter their intake based on the perceived 
benefit or harm of a food or food group. Patients who reported that red meat, dairy, or 
sugar exacerbated their symptoms had a significantly lower intake of those items, while 
patients who reported that cereal, milk, fruit, or whole grains improved symptoms had a 
significantly higher intake of those items. These studies provide foundational evidence 
that dietary restriction is a relevant eating behavior in the IBD population.  
Disordered Eating in the IBD Population 
The fact that many IBD patients engage in restrictive eating behaviors indicates that 
the population may be at a high risk for disordered eating and eating disorders (Quick, 
Byrd-Bredbenner, & Neumark-Sztainer, 2013). Research on the prevalence of disordered 
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eating in the IBD population is limited; however, using the Eating Attitudes Test eating 
disorder screener, Wabich, Bellaguarda, Joyce, Keefer, and Kinsinger, (2020) found that 
13% of IBD patients are at a high risk for an eating disorder. When IBD patient responses 
to the Eating Attitudes Test screener were analyzed by gender, high eating disorder risk 
increased to between 18–20% for female IBD patients (Satherley, Howard, & Higgs, 
2016; Wabich et al., 2020).  
In a retrospective study, Wotton, James, and Goldacre (2016) examined the 
comorbidity of autoimmune disease and eating disorder by calculating the likelihood that 
people who were admitted to the hospital for an eating disorder were prospectively 
admitted again for an autoimmune disorder and vice-versa. Wotton et al. (2016) 
calculated a risk ratio, comparing the likelihood that the control group, people who were 
admitted to the hospital for “minor conditions,” were prospectively hospitalized for an 
autoimmune disease or an eating disorder. Compared to the control group, females who 
were initially admitted for anorexia nervosa were about two times more likely to be 
hospitalized for UC and CD in the future (2.25 and 1.97, respectively). Females who 
were initially admitted for CD were 2.82 times more likely than the control group to be 
hospitalized for anorexia nervosa in the future and females who were initially admitted 
for UC were 1.91 times more likely than the control group to be hospitalized for anorexia 
nervosa in the future. These results show that severe eating disorders are present in 
female IBD patients and that there may be a correlation between the two diagnoses.  
When specified, the primary eating disorders that these studies investigated were 
anorexia nervosa and bulimia nervosa; however, based on the knowledge that IBD 
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patients engage in food avoidance and restrictive eating, they may also be at a high risk 
for the eating disorder diagnosis, avoidant/restrictive food intake disorder (ARFID). 
ARFID was introduced into the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-5) in 2013 to broaden the scope of what was previously known as feeding disorder 
of infancy and early childhood. The new ARFID diagnosis is applicable to individuals of 
any age whose avoidant/restrictive eating behaviors but lead to insufficient caloric and/or 
nutrient intake, causing at least one of the following symptoms: weight loss, nutritional 
deficiency, dependence on nutritional supplements, or psychosocial impairment. The 
DSM-5 describes three categories that can lead to the symptoms of ARFID: avoidance of 
many foods based on their sensory properties (“picky eating”), low appetite or limited 
interest in eating, and fear of negative consequences, such as choking or vomiting from 
eating (American Psychiatric Association, 2013). Clinical diagnostic criteria for ARFID 
requires a disturbed eating or feeding experience that is not motivated by weight or body 
image concerns and that results in one or more of the following outcomes: nutritional 
deficiency as a result of insufficient food intake, significant weight loss, dependence on 
enteral or oral supplements, or impaired psychological function. If a patient also has a 
mental or physical illness, the feeding disturbance must exceed any feeding disturbances 
that are typically associated with the condition or disorder. Finally, patients who do not 
have sufficient food access or who have cultural practices that change eating patterns 
should not be diagnosed with ARFID (Katzman, Norris, & Zucker, 2018).  
Because of the limited amount of research on eating disorders in the IBD population 
and the relatively new diagnostic criteria of ARFID, there are no studies that have looked 
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at the prevalence of ARFID in IBD patients specifically; however, a case study from 
Ilzarbe et al. (2017) highlights that this may be a relevant diagnosis that is overlooked in 
the IBD population. The 20-year-old subject of the case study had a CD diagnosis and an 
eating disorder not otherwise specified. Ilzarbe et al. (2017) found the patient to have 
significant weight loss in the previous year and described her eating habits as restrictive, 
explaining that the patient is more comfortable using enteral nutrition. They also 
specified that the patient did not have body image disturbance or fear of gaining weight. 
While the patient was diagnosed with eating disorder not otherwise specified, her 
symptoms meet the criteria for ARFID, and this would have been an appropriate 
diagnosis that may have led to a more targeted and effective treatment regimen. This case 
study highlights the concurrent incidence of IBD and ARFID while also showing that 
without awareness and screenings, ARFID goes undiagnosed. 
In two studies that investigated the prevalence of ARFID in patients with GI 
disorders, researchers found that between 12–21% of participants met the ARFID 
diagnostic criteria (Harer, Jagielski, Riehl, & Chey, 2019; Zia, Riddle, DeCou, McCann, 
& Heitkemper, 2017). Harer et al. (2019) retrospectively evaluated the medical charts of 
adult gastroenterology patients who had been referred to gastroenterology behavioral 
health providers and found that 12.6% met the criteria for ARFID. Of those that met the 
ARFID criteria, 14.3% had an IBD diagnosis. Zia et al. (2017) measured the prevalence 
of many eating disorders, including ARFID, in adults with functional gastrointestinal 
disorders. Results showed that 21% of participants met the criteria for ARFID. These 
studies confirm the theoretical framework that ARFID is a relevant diagnosis for patients 
	 19 
with IBD and they affirm the need to investigate the prevalence of ARFID in the IBD 
population specifically, especially considering that they are a population that is at a high 
risk for impaired nutritional status. 
To evaluate ARFID diagnosis Harer et al. (2019) retrospectively evaluated the 
medical charts of participants, screening for DSM-5 ARFID diagnostic criteria. The 
authors did not go into detail on the screening process; however, this retrospective 
process could have missed critical elements that may have led to, or invalidated, an 
ARFID diagnosis. For example, determining food access or cultural practices may not 
have been possible the medical records of participants. In their adult cohort, Zia et al. 
(2017) implemented the ARFID Canadian Pediatric Surveillance Program Questionnaire, 
an instrument validated for use in a child population that may not have been appropriate 
for the adult population of the study.  
Another recent instrument that has been validated to screen for ARFID risk in an 
adult population is the Nine Item Avoidant/Restrictive Food Intake Disorder Screener 
(NIAS) (Zickgraf, & Ellis, 2018). The NIAS is structured based on the three domains of 
eating disturbances in the DSM-5: avoidance of foods due to sensory properties, poor 
appetite or limited interest in eating, and fear of negative consequences from eating. The 
NIAS has been used to identify avoidant and restrictive eating behaviors in children, 
adolescents, adults who are healthy, and adults who were previously determined to have 
eating difficulties (Elkins, & Zickgraf, 2018; Zickgraf, & Elkins, 2018; Zickgraf, Ellis, & 
Essayli, 2019). It has not been used in the IBD population; however, in a study of adult 
patients with symptoms of gastroparesis and dyspepsia, the NIAS was used to screen for 
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ARFID (Murray, Jehangir, Silvernale, Kuo, & Parkman 2020). 
To establish a clinical cutoff score, Ellis, Zickgraf, Whited, and Galloway (2017) 
implemented the NIAS in a general sample of college students and in a sample of adults 
who were known to have eating difficulties. Participants completed the NIAS and an 
ARFID Symptoms Checklist that explicitly assesses the DSM-5 ARFID diagnostic 
criteria. Using a receiver operating characteristic curve analysis and the area under the 
curve (AUC), researchers determined that the NIAS was a good screener for ARFID in 
both the general and selected samples (AUCgeneral= 0.87, AUCselected= 0.80). In the general 
sample a cutoff of 24 demonstrated good sensitivity (0.74) and specificity (0.84). In the 
selected sample, a cutoff score of 28 demonstrated adequate sensitivity (0.71) and 
specificity (0.68). Researchers hypothesized that the group selected for eating difficulties 
required a higher cutoff score because the symptoms associated with their eating 
difficulties may have added complexity to their cases that could not be accounted for by 
the screener.  
Malnutrition in the IBD Population 
Malnutrition in IBD patients is a serious condition as it is associated with negative 
outcomes such as increased risk of non-elective surgery, increased length of hospital stay, 
and increased mortality (Forbes et al., 2017). Many studies, using a variety of 
methodologies, have shown that malnutrition is prevalent in the IBD population. In one 
study that used unintentional weight loss as an indicator for malnutrition, researchers 
found that 68.4% of IBD patients with active disease met the criteria for malnutrition and 
that 31.6% met the criteria for severe malnutrition (Mijač, Janković, Jorga, & Krstić 
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(2010). Similarly, Benjamin, Makharia, Kalaivani, & Joshi (2008) found that 52.6% of 
patients with active or quiescent CD could be classified as malnourished based on a 
collection of anthropomorphic measurements. Benjamin et al. (2008) also found that 
participants with active CD were 7.5 times likelier to be malnourished than participants 
with quiescent CD. 
While it is important to estimate the prevalence of malnutrition, these studies do not 
identify any nutrients that are specifically associated with malnutrition in IBD. Filippi, 
Al-Jaouni, Wiroth, Hébuterne, & Schneider (2006) investigated specific deficiencies by 
collecting data on both dietary intake as well as serum nutritional biochemical markers in 
participants with quiescent CD and a matched control group. From an analysis of  3-day 
prospective food records that were completed by participants, researchers found that 
female CD patients had significantly lower mean daily intakes of β-carotene, vitamins 
B1, B6, and C, and magnesium and significantly higher daily intakes of zinc compared to 
controls. Male CD patients had significantly lower mean daily intakes of β-carotene and 
vitamin C. From the biochemical analysis, researchers found that 84% of participants had 
low plasma concentration of vitamin C and copper, 77% had low plasma concentrations 
of niacin and 65% had low plasma concentration of zinc. Using the Nutritional Risk 
Index and albumin levels (Prasad et al., 2016), researchers found that 29% of participants 
were at moderate or severe risk for malnutrition.  
These studies demonstrate the prevalence of malnutrition in IBD, but they do not 
specify the association with restriction. Given the evidence that people with IBD do 
restrict their intake according to their dietary beliefs, it is reasonable to expect that they 
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may have nutrient deficiencies secondary to their dietary restriction. Jowett et al. (2004) 
addressed this question by looking at three high-risk nutritional factors for IBD patients 
who restrict their diets: folate, calcium, and fiber. Researchers did not find a significant 
difference in folate or fiber intake between participants who believed that foods rich in 
folate or fiber (ex. legumes, vegetables) were detrimental and those who did not. Folate 
sufficiency in the IBD population was confirmed when Marcil et al. (2019) measured 
serum folate and found that only 2.6% of participants had abnormally low results. Jowett 
et al. (2004) did find that participants who believed that dairy was detrimental had a 
significantly lower median calcium intake compared to participants who did not hold this 
belief. This study shows that food beliefs and eating behaviors can impact micronutrient 
intake and the under-consumed micronutrients identified by Filipi et al. (2006) should 
also be investigated. 
One patient-reported screening instrument that identifies patients at nutritional risk 
and is designed to reduce the burden of a comprehensive nutritional assessment in the 
clinical setting is the Patient-Generated Subjective Global Assessment Short Form (PG-
SGA SF). The PG-SGA SF is a shortened version of the full-length Patient Generated-
Subjective Global Assessment which was developed as a continuous score with a low 
score indicating well-nourished nutritional status and a high score indicating higher risk 
of malnutrition (Jager-Wittenaar, & Ottery, 2017). The four areas of the PG-SGA SF 
address: weight history and acute weight change, changes in dietary intake, symptoms 
that have impacted dietary intake, and changes to activities and function. The full-length 
PG-SGA has been validated to measure nutritional risk in in ambulatory oncology 
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settings (Bauer, Capra, & Ferguson, 2002; Isenring, Bauer, & Capra, 2003), an internal 
medicine ward (Pinho et al., 2017), and in non-oncology surgery patients (Huang et al., 
2014). Subsequently, the PG-SGA SF has been validated as an analogous tool to the 
Patient Generated-Subjective Global Assessment (PG-SGA) for screening for nutritional 
risk (Abbott, Teleni, McKavanagh, Watson, McCarthy, & Isenring, 2016; Gabrielson et 
al., 2013). In their validation study on outpatient oncology patients, Gabrielson et al. 
(2013) found a strong, significant correlation between the full-length PG-SGA and the 
PG-SGA SF (r = 0.984, P < 0.001). They also found that, with a sensitivity of 93.8% and 
a specificity of 77%, the PG-SGA SF is comparable to the full-length PG-SGA 
(sensitivity: 0.97, specificity: 0.77). Possible PG-SGA SF scores range from 0–36 and 
Gabrielson et al. (2013) found that the optimal cutoff score for capturing patients with 
malnutrition was six or greater. While the PG-SGA has been used in IBD studies 
(Casanova et al., 2017; Lim, Kim, Hong, & Kim, 2014), it has not been validated in an 
IBD population.  
Dietary Assessment Methodology in IBD 
Many types of dietary assessment instrumentation have been used in the IBD 
population. Dietary intake assessment is necessary to address research questions that 
investigate diet and disease etiology, disease course, and symptom management. Dietary 
intake must also be assessed when evaluating the dietary adherence of participants in 
intervention studies. Researchers have not established one, universally accepted 
methodology for evaluating dietary intake in any population and in the IBD literature 
many methodologies have been used to assess dietary intake, including 24-hour recalls, 
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FFQ, diet histories, and dietary records. In a review of 56 articles investigating diet and 
IBD course (Table 1), twenty-six implemented FFQs, eight implemented diet recalls, 
fourteen implemented diet records, four implemented dietary screeners, and six 
implemented study designed instruments. Some instruments were validated in the study 
population (Opstelten et al., 2018; Vagianos et al., 2016) while others were validated in 
populations different from that of the study (Geerling et al., 2000; Gilman, Shanahan, & 
Cashman, 2006; Vagianos et al., 2007). Some of the instruments were validated in the 
nutritional outcome relevant to the study (Pedersen et al., 2017; Vernia et al., 2014) and 
others were novel and not validated outside of their study (Kyaw et al., 2014; Magee et 
al., 2005). Many studies also collected biochemical samples to verify participant intake of 
the nutrient of interest and to investigate the  nutrient status of participants (Gee, Grace, 
Wensel, Sherbaniuk, & Thomson, 1985; Geerling et al., 2000; Papada, Amerikanou, 
Forbes, & Kaliora, 2020; Ripoli, Miszputen, Ambrogini, & Carvalho, 2010; 
Silvennoinen, Lamberg-Allardt, Karkkainen, Niemela, & Lehtola, 1996; Vagianos et al. 
2007 ). For example, Vagianos et al. (2007) implemented a FFQ, food diary, and 
biochemical sample to assess the specific nutrient intake and nutrient status of IBD 
patients. Using this combination of instrumentation, researchers were able to associate 
dietary intake with serum levels of micronutrients like folate, vitamin B12, and vitamin 
B6. While serum levels of specific nutrients do not always reflect accurate nutrient status, 
when it is feasible and appropriate, biochemical samples can add validation to dietary 
assessment data. Overall, establishing a study design that gathers accurate, thorough 
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Table 1. Articles reviewed for dietary assessment literature review, organized by primary outcome of interest. 
Author, Year, 
Country 
Outcome Disease Type 
(Sample Size) 
Study Design Assessment 
Method 
Assessment Instrument 





Habitual Diet  
UC; CD (69) 
 
Cross-sectional FFQ;  
Diet History 
Validated in pregnant Dutch 
population. Specific to fat and 
antioxidant intake.  










Vitamin D;  
Vitamin K;  
Habitual Diet 
 








UC; CD (65) Cross-sectional FFQ Validated for use in chronic 
disease intervention studies. 
 










Calcium UC; CD (187) Cross-sectional FFQ Validated to measure calcium 
intake in Italian population. 






UC, CD with 
Ileostomies (10) 















Table 1 (cont.). Articles reviewed for dietary assessment literature review, organized by primary outcome of interest. 
Author, Year, 
Country 
Outcome Disease Type 
(Sample Size) 
Study Design Assessment 
Method 
Assessment Instrument 






UC (112) Randomized 
Control Trial 





UC; CD; IBS 
(180) 
Prospective Study Designed 
Questionnaire 
Designed to measure adherence 
























CD (86) Cross-sectional FFQ MedDiet scoring method 






CD (99) Case-Control, 
Cross-sectional 
 











FFQ Validated in Japanese 
population. 







CD Active (18) Randomized 
Control Trial 
Food Diary — 
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Table 1 (cont.). Articles reviewed for dietary assessment literature review, organized by primary outcome of interest. 
Author, Year, 
Country 
Outcome Disease Type 
(Sample Size) 





Fiber UC Remission; 
CD Remission 
(1,619)  
Prospective Dietary Screener Validated 26-item Dietary 
Screener Questionnaire from the 












quantitative FFQ, developed 
with guidelines from National 




















CD (178) Intervention 
Study 






































FFQ Comprehensive Nutrition 
Assessment Questionnaire 
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Table 1 (cont.). Articles reviewed for dietary assessment literature review, organized by primary outcome of interest. 
Author, Year, 
Country 
Outcome Disease Type 
(Sample Size) 










UC; CD (245) Cross-sectional FFQ Dietary History Questionnaire-













Canadian Health Measures 
Survey; Study Designed Food 













Habitual Diet:  
     
Benjamin, 2008, 
India 
Habitual Diet CD (112) Cross-sectional 24-Hour Recall; 
FFQ 
Validated to measure energy and 















Habitual Diet UC; CD (2,329) Cross-sectional Dietary Screener Validated 26-item Dietary 
Screener Questionnaire from the 




Habitual Diet CD Remission 
(54) 
 






Habitual Diet UC; CD (114) Cross-sectional 48-Hour Recall — 
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Table 1 (cont.). Articles reviewed for dietary assessment literature review, organized by primary outcome of interest. 
Author, Year, 
Country 
Outcome Disease Type 
(Sample Size) 










FFQ FFQ validated in Portuguese 
population. 
 
Han, 2020, USA Habitual Diet UC; CD (454) Cross-sectional Dietary Screener Validated 26-item Dietary 
Screener Questionnaire from the 
National Cancer Institute. 
Imes, 1987, 
Canada 






Habitual Diet UC; CD (60) Cross-sectional FFQ 122 item food list based on 
Block FFQ 
Jowett, 2004, UK 
 
Habitual Diet UC (183) Prospective FFQ Validated in UK population.  
Jowett, 2004, UK 
 
Habitual Diet UC (183) Prospective FFQ Validated in UK population.  
Kakodkar, 2015, 
USA 



















Habitual Diet UC; CD (41) Cross-sectional 
 
24-Hour Recall — 
Magee, 2005, 
UK 






Habitual Diet UC; CD (165) Cross-sectional; 
Longitudinal 
 




Habitual Diet UC (65) Longitudinal 3-Day Food 
Record; FFQ 
No citation for FFQ. 
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Table 1 (cont.). Articles reviewed for dietary assessment literature review, organized by primary outcome of interest. 
Author, Year, 
Country 
Outcome Disease Type 
(Sample Size) 





Habitual Diet UC; CD (103) Cross-sectional FFQ Adapted from EPIC-Norfolk 
FFQ. Validated in small group 











Habitual Diet UC Remission 
(59) 
Cross-sectional 24-Hour Recall Multi-pass method. 
Vagianos, 2007, 
Canada 
Habitual Diet UC; CD (126) Cross-sectional FFQ; Food Diary Validated for fat and calcium 
intake of menopausal women. 
Vidarsdottir, 
2016, Iceland 








Habitual Diet UC; CD (388) Cross-sectional Diet History 
Questionnaire 




Habitual Diet UC; CD (322) Cross-sectional; 
Case-control 
 
FFQ Validated in Chinese population. 



















UC (103) Cross-sectional 7-Day Food 
Diary 
Validated through EPIC study. 
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Table 1 (cont.). Articles reviewed for dietary assessment literature review, organized by primary outcome of interest. 
Author, Year, 
Country 
Outcome Disease Type 
(Sample Size) 
Study Design Assessment 
Method 
Assessment Instrument 

















Folate UC; CD (10) Prospective 24-Hour Recall — 
Skolmowska, 
2019, Poland 
Isoflavone UC Remission 
(56) 
Cross-sectional 3-Day Food 
Record 
— 
      
Suibhne, 2012, 
Ireland 
Vitamin D CD (151) Cross-sectional, 
Case-control. 
FFQ Validated for calcium and 
vitamin D intake. 
CD: Crohn’s Disease; UC: Ulcerative Colitis; FFQ: Food Frequency Questionnaire 
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Conclusion 
This literature review describes the relationship between IBD and diet and 
emphasizes the complexity of dietary assessment in the IBD populations. It also 
highlights the challenge of reproducing generalizable dietary research due to suboptimal 
dietary assessment methodologies and observational study designs. In order to draw 
strong, evidence-based conclusions about the role of diet in the treatment and 
maintenance of IBD, rigorous randomized controlled trials examining the efficacy of 
diets like the SCD and LFD are necessary. Nevertheless, it is clear that people with IBD 
hold strong dietary beliefs and alter their dietary intake in an effort to manage their 
disease status and symptoms.  
Due to the prevalence of malnutrition in the IBD population and the associated 
negative outcomes, it is necessary to assess and quantify the extent to which the dietary 
beliefs of IBD patients lead to disordered, restrictive eating behaviors and their impact on 
nutritional status. Currently, there is no research investigating ARFID risk in the IBD 
population, nor is there any research exploring the association between ARFID risk and 
nutritional status. Chapter two will describe the prevalence of ARFID risk in the adult, 
IBD population and it will examine the relationship between ARFID risk and nutritional 
status. With more information on avoidant and/or restrictive eating behavior and its 
association with malnutrition, health care professionals can equip themselves with tools 
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Background: Inflammatory bowel disease (IBD) patients often alter their normal dietary 
behaviors. The prevalence of avoidant restrictive food intake disorder (ARFID) and its 
impact on nutritional status among IBD patients are unknown. The purpose of this study 
was to describe the prevalence of and risk factors for ARFID risk and to examine the 
relationship between ARFID risk and nutritional status in IBD patients.  
Methods: This cross-sectional study recruited adult IBD patients from an outpatient 
clinic. ARFID risk was measured using the Nine-Item ARFID Screen (NIAS). Nutritional 
status was measured with the Patient Generated-Subjective Global Assessment (PG-
SGA). Patient demographics, disease characteristics, and medical history were abstracted 
from medical records.  
Results: Of the 161 participants, 17% were at ARFID risk. Ninety-two percent avoid 
food(s) during a flare, while 74% avoid food(s) in the absence of a flare. Participants who 
avoid food, regardless of disease status had significantly higher ARFID risk scores 
compared to those who do not avoid food. Patients who reported symptoms of diarrhea, 
pain, no appetite, and fullness were significantly more likely to be at ARFID risk. There 
was a positive relationship between ARFID risk and PG-SGA score (rs = 0.196, P = 
0.024).  
Conclusion: Avoidant eating behaviors are prevalent in IBD patients. The positive 
correlation between ARFID risk score and PG-SGA score indicates that ARFID risk and 
malnutrition risk are associated. These findings suggest that IBD patients should have 
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regular visits with registered dietitians who can monitor both disordered eating behaviors 
and malnutrition risk, directing appropriate nutrition intervention. 
Keywords: inflammatory bowel disease, ulcerative colitis, Crohn’s disease, 






















Inflammatory bowel disease (IBD) is a chronic inflammatory illness that 
encompasses two diagnoses: Crohn’s disease (CD) and ulcerative colitis (UC). Both 
diseases are characterized by periods of heightened activity and remission. Increased 
disease activity is commonly referred to as a flare, and signs and symptoms include 
abdominal pain, diarrhea, bloody stool, and/or frequent bowel movements.1 There is no 
cure for CD or UC and the best outcome for people with IBD is to remain in remission, 
while managing uncomfortable and disruptive functional gastrointestinal symptoms. 
Disease etiology and status in IBD is multifactorial and influenced by a combination of 
genetic and environmental factors.1 One of the environmental factors that people with 
IBD can manipulate is diet. While many diets have been suggested for the management 
of functional gastrointestinal symptoms and disease management, there is a lack of easily 
accessible, conclusive, dietary recommendations on which patients can make dietary 
choices.2 Even so, it is well documented that people with IBD believe that their dietary 
choices influence their disease status.3,4 This leads patients with IBD to limit their dietary 
intake based on advice from the internet or general clinical practitioners.4,5 When this 
independent, unsupervised approach at dietary intake is combined with confusion about 
what defines the most appropriate diet for IBD, patients may alter their normal dietary 
choices and behaviors and may run the risk of developing restrictive eating behaviors that 
can result in deficient nutritional intake, increasing their risk for malnutrition.6,7  
In 2013 avoidant/restrictive food intake disorder (ARFID) was introduced into the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5) to broaden the scope of 
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what was previously known as feeding disorder of infancy and early childhood. The new 
ARFID diagnosis is applicable to individuals of any age whose avoidant/restrictive eating 
behaviors lead to insufficient caloric and/or nutrient intake and cause at least one of the 
following symptoms: weight loss, nutritional deficiency, dependence on nutritional 
supplements, or psychosocial impairment.9 The DSM-5 describes three categories that 
can lead to the symptoms of ARFID: avoidance of many foods based on their sensory 
properties (“picky eating”); low appetite or limited interest in eating; and fear of negative 
consequences, such as choking, vomiting, or other painful or uncomfortable symptoms 
that might be associated with eating, such as abdominal pain and bloating.9-11 Because of 
the recency with which ARFID was added to the DSM-5, there have not been any large 
scale epidemiological studies conducted to measure the prevalence in the general 
population10; however, studies have shown that the prevalence of ARFID in patients with 
gastrointestinal disorders is 12–21%.11,12 While these studies demonstrate that ARFID is 
prevalent in the gastrointestinal disorder population, they do not address how it impacts 
the nutritional status of patients.  
The association between restrictive eating and nutrition status is important to 
investigate because IBD patients are at a higher risk for malnutrition. Studies have shown 
that between 29–68% of IBD patients are malnourished6,13,14 and have significantly lower 
mean daily intakes and plasma concentrations of essential micronutrients compared to 
healthy controls.6 
These studies demonstrate the prevalence of malnutrition in IBD, but they do not 
address any association with restrictive eating behaviors. Given the evidence that people 
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with IBD do restrict their intake, it is reasonable to expect that patients with ARFID may 
be at an even higher risk for malnutrition. The three aims of this study were to describe 
the prevalence of ARFID risk in the adult, IBD population, to identify risk factors for 
ARFID, and to examine the relationship between ARFID risk and nutritional status. With 
more information on the prevalence of restrictive eating and its association with 
malnutrition, practitioners can equip themselves with tools to provide targeted screenings, 
prevention, and treatment for high risk patients going forward. 
Materials and Methods 
Participant Recruitment 
This cross-sectional study was conducted at the University of California, Los Angeles 
(UCLA) Center for Inflammatory Bowel Diseases from October 2019 to March 2020. 
English speaking, adult patients receiving care at this outpatient clinic with a confirmed 
IBD diagnosis (Crohn’s disease, ulcerative colitis, or IBD-unknown) were invited to 
participate in the study. Participants were excluded from the study if they had a medical 
diagnosis of celiac disease, active anorexia nervosa or bulimia nervosa, an unmanaged 
psychological disorder, alcohol abuse or if they were pregnant. Written consent was 
obtained from eligible participants. The study was approved by UCLA’s Institutional 
Review Board and a data sharing agreement was established between San José State 
University and UCLA.  
Demographic and Medical History Collection  
Data were collected from participants by hardcopy survey before scheduled in-clinic 
appointments. Medical data regarding the age, gender, race, ethnicity, substance use, 
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disease subtype (CD, UC, IBD-unknown), and disease duration of participants were 
abstracted from electronic medical records. Current medication use was also identified in 
electronic medical records and was categorized as aminosalicylates, steroids, 
immunomodulators or biologics. CD location was classified as ileal, colonic, ileocolonic, 
upper GI, or unknown and CD behavior was classified as inflammatory, structuring, 
fistulizing, or perianal. UC extent was classified as rectum, left colon, pancolon, or 
unknown. Participants were identified as having no flare, recent flare (within 60 days), or 
active flare and previous small bowel resection, colectomy, or ileoanal anastomosis 
pouch surgeries were recorded.  
Assessment of Avoidant/Restrictive Food Intake Disorder Risk 
Avoidant/restrictive food intake disorder (ARFID) risk was measured using a the 
Nine Item Avoidant/Restrictive Food Intake Disorder Screen (NIAS) which has been 
validated in a nationally representative subject pool, an undergraduate student population, 
and in a population selected for eating difficulties.15 The screening tool is organized into 
three specific domains of ARFID that have been identified by the DSM-5, each of which 
is addressed by three questions. The three domains assess eating restriction due to picky 
eating, poor appetite/limited interest in eating, and fear of negative consequences from 
eating. Each domain includes three questions and the scores range from 0 to 15 max. 
When compared to other instruments that measure picky eating, appetite, and fear, the 
ARFID risk screening tool has high internal consistency (Cronbach’s α = 0.90), test-retest 
reliability (ICC = 0.65, 95% CI: 0.56–0.72), and convergent/discriminant validity for 
adults aged 18–65. Questions are based on a 6-point Likert scale with 0 indicating 
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“strongly disagree” and 5 indicating “strongly agree.” Survey responses were totaled for 
an ARFID risk score that ranged from 0–45. Ellis et al.16 demonstrated that a total cutoff 
score of 24 showed good sensitivity (0.74) and specificity (0.84) for identifying a positive 
ARFID diagnosis. Additional questions were added to the survey to provide more detail 
about the eating behaviors of participants. One question asked whether the participant has 
consistent access to food and another asked whether they make dietary choices based in 
specific cultural practices. Participants were also asked “during a flare do you avoid any 
of the following foods: lactose containing foods, spicy foods, alcohol, wheat products, 
deep fried/fatty foods, caffeine, or other” and “during remission do you avoid any of the 
following foods: lactose containing foods, spicy foods, alcohol, wheat products, deep 
fried/fatty foods, caffeine, or other.” If participants answered yes to one or more foods, 
they were categorized as avoiding food. If they answered no, they were categorized as not 
avoiding food.   
Assessment of Nutritional Status 
Nutritional status risk was measured using an adapted version of the validated Scored 
Patient-Generated Subjective Global Assessment Short Form (PG-SGA).17 The PG-SGA 
is based on self-reported criteria and has been validated to measure nutritional risk in 
ambulatory oncology settings,18 an internal medicine ward,19 and in non-oncology 
surgery patients.20 The PG-SGA has four sections covering recent weight change, 
changes in food intake, symptoms with possible nutrition impact, and activities and 
functions and has been described elsewhere.17 Of importance to this study was the overall 
PG-SGA score (0(low risk)–36(high risk)) which indicates malnutrition risk.17 Gabrielson 
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et al.21 found that a cutoff score of six or greater had high sensitivity (0.938) and 
specificity (0.776 ) and was optimal for capturing patients with confirmed malnutrition. 
Percent weight loss over past month was calculated from the patient report of current 
weight and weight from one-month prior on the PG-SGA. To determine nutrition impact 
symptoms, responses to the third section of the PG-SGA were used. Participants were 
asked to select symptom(s) that kept them from eating enough during the past two weeks 
and were instructed to select all symptoms that apply. IBD related symptoms were 
reviewed for this study and included: no appetite, just did not feel like eating; vomiting; 
nausea; diarrhea; constipation; smells bother me; feel full quickly; fatigue; pain; and 
other.  
Data Analysis 
All statistical analyses were performed using SPSS and results were considered 
statistically significant when P < 0.05. Continuous variables were tested for normalcy 
using the Shapiro-Wilk test. Parametric data were summarized as means (± standard 
deviation (SD)) or percentages and non-parametric data were summarized as median 
(interquartile range (IQR)). To test for significant differences between ARFID domains, 
the Kruskal-Wallis test was performed. The Kruskal-Wallis test was also used to test for 
differences in ARFID risk score across clinical characteristics (BMI, flare status, gender, 
IBD type). Any significant differences were analyzed post-hoc using a Mann-Whitney U 
test, adjusted with a Bonferroni correction. Multiple linear regression was used to 
evaluate associations between clinical characteristics and ARFID risk score. Correlations 
between total ARFID risk score, and measures of nutritional status were evaluated using 
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the Spearman correlation coefficient. Nominal results were tested for dependence using 
the chi-square test. If criteria for the chi-square test were not met the Fisher’s Exact test 
was used.  
Ethical Considerations 
Consent was obtained from all participants and the ethics committee at UCLA 




One hundred and sixty-one patients were enrolled in the study, completed the ARFID 
risk questions, and were included in this study. Of the 161 participants, 73 had CD 
(45.3%), 83 had UC (51.6%), and 5 had IBD-unclassified (3.1%). Eighty-eight 
participants were female (54.7%) and 73 were male (45.3%). The average age of 
participants was 41.1 years (SD ± 15.5). The majority of participants were white (n = 
114, 70.8%), 14 were Hispanic (8.7%), 3 were Asian (1.9%), and 6 were black (3.7%) 
(Table 1). The mean duration of IBD diagnosis was 13.0 years (SD ± 11.6). The majority 
of patients had no recent flare (n = 110, 68.3%), 11 (6.8%) patients had a flare within 60 
days, and 40 (24.8%) patients had an active flare. Twenty-two (13.7%) participants 
reported that they make dietary choices based in cultural practices. Fifty-four percent of 
participants had a BMI in the normal range, 5.6% were underweight, and 40.4% of 
participants were overweight/obese (mean 24.7; SD ± 4.6). BMI did not differ between 
IBD types (Kruskal-Wallis H: 2.395, P = 0.302) (Table 2). 
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TABLE 2. Demographic and Clinical Characteristics  
 
  
n, (%) Mean  
(± SD) 
Median (IQR) 
Age 161 (100) 41.1 (15.5) 38.3 (21.2) 
Gender 161 (100)   
Female 88 (54.7)   
Male 73 (45.3)   
BMI  161 (100) 24.7 (4.6) 23.8 (5.5) 
Underweight 9 (5.6) 17.2 (1.2) 17.5 (1.3) 
Normal 87 (54.0) 22.2 (1.6) 22.3 (2.4) 
Overweight 47 (29.2) 27.1 (1.5) 27 (2.4) 
Obese 18 (11.2) 34.0 (3.4) 33 (5.1) 
Disease Duration 159 (98.8) 13.0 (11.6) 10.0 (10.0) 
IBD Type 161 (100)   
Crohn’s disease 73 (45.3)   
Ulcerative colitis 83 (51.6)   
IBD-U 5 (3.1)   
Race 161 (100)   
Asian 3 (1.9)   
Black 6 (3.7)   
White 114 (70.8)   
Other 38 (23.6)   
Hispanic 161 (100)   
Yes 14 (8.7)   
No 147 (91.3)   
CD Location 73 (45.3)   
Ileal 21 (28.8)   
Colon 16 (21.9)   
Ileocolonic 35 (47.9)   
Upper Gastrointestinal 1 (1.4)   
CD Behavior 73 (45.3)   
Inflammatory 36 (49.3)   
Stricturing 17 (23.3)   
Fistulizing 21 (28.8)   
Perianal 25 (15.5)   
Number of EIM 161 (100)   
0 121 (62.1)   
1 27 (16.8)   
2+ 13 (8.1)   
Flare Status 161 (100)   
No Recent Flare 110 (68.3)   
Recent Flare within 60 Days 11 (6.8)   
Active Flare 40 (24.8)   
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TABLE 2 (cont.). Demographic and Clinical Characteristics  
 
  
n, (%) Mean  
(± SD) 
Median (IQR) 
Current Medications    
Aminosalicylates 64 (39.8)   
Steroids 38 (23.6)   
Immunomodulators 49 (30.4)   
Biologics 88 (54.7)   
Number of Prior Biologics 161 (100)   
0 109 (67.8)   
1 23 (14.3)   
2+ 29 (18.0)   
Number of Surgeries 161 (100)   
0 134 (83.2)   
1 18 (11.2)   
2 9 (5.6)   
Surgical History    
None 134 (83.2)   
Small Bowel Resection 15 (9.3)   
Colectomy 14 (8.7)   
Ileal Pouch-Anal Anastomosis 7 (4.3)   
Current Substance Use    
Smoking 6 (3.7)   
Drugs 20 (12.8)*   
Alcohol 73 (45.3)   




Avoidant/Restrictive Food Intake Disorder Risk  
The first aim of this study was to describe the prevalence of ARFID risk indicated by 
a score of ≥ 2416 in an IBD population in Southern California. The median overall ARFID 
risk score was 12 (IQR 7–20) with 17% of participants scoring ≥ 24 (Table 3). Of the 
three domains that were assessed by the ARFID risk screening questionnaire, the fear of 
negative consequences domain scored the highest with a median score of 5 (IQR 3–9) 
and was significantly higher than the poor appetite domain which had a median score of 3 
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(IQR 0–6, P < 0.001) (Table 3). ARFID risk score was greater for participants who make 
dietary choices based in cultural practices (median 18, IQR 9–26) compared to 
participants who do not make dietary choices based in cultural practices (median 12, IQR 
7–19, P = 0.49) (Table 3). Ninety-two percent of participants (n = 148) avoid one or more 
foods when they are having a flare, while 74% (n = 119) avoid one or more foods in the 
absence of a flare. In a flare, 54% (n = 87) of participants reported that they avoid lactose 
containing foods, 71% (n = 114) reported that they avoid spicy foods, 70% (n = 112) 
reported that they avoid alcohol, 38% (n = 61) reported that they avoid wheat products, 
67% (n = 108) reported that they avoid deep fried/fatty foods, and 45% (n = 73) reported 
that they avoid caffeine. In absence of a flare, 37% (n = 60) of participants reported that 
they avoid lactose containing foods, 43% (n = 70) reported that they avoid spicy foods, 
40% (n = 64) reported that they avoid alcohol, 23% (n = 37) reported that they avoid 
wheat products, 39% (n = 62) reported that they avoid deep fried/fatty foods, and 22% (n 
= 36) reported that they avoid caffeine. In both flare and no flare, participants commonly 
wrote in that they avoid meat and vegetables.  
The second aim of this study was to identify risk factors for ARFID. There were no 
significant differences in ARFID risk score across IBD type, flare status, or gender 
(Table 3). Participants who reported avoiding food during a flare and in the absence of a 
flare had significantly higher ARFID risk scores (P < 0.001, P = 0.030, respectively) 
(Table 3). Forty-six percent of participants reported one or more symptom that prevented 
eating enough over the past two weeks. The most frequently reported problems were 
fatigue (17%); no appetite, just did not feel like eating (16%); diarrhea (16%); pain 
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(15%); feel full quickly (14%); and nausea (13%). Participants who responded 
affirmatively to symptoms of diarrhea, pain, no appetite, and fullness were significantly 
more likely to have an ARFID risk score above 24 (P = 0.009, P = 0.002, P ≤ 0 .001, P 
≤ 0.001, respectively). In the multiple linear regression analysis, participants with prior 
biologic use were found to have an ARFID score 3.3 points higher than participants with 
no prior biologic use (95% confidence interval 0.30–6.3, P = 0.033). Age, gender, alcohol 
consumption, disease activity, flare status, steroid use, and colon resection were not 
found to be associated with higher ARFID risk scores. 
TABLE 3. Comparison of Avoidant/Restrictive Food Intake Disorder (ARFID) Risk Score by 










Total ARFID Risk Score 
(minimum: 0 maximum: 45) 
161 (100) 12 (7–20)   
 
Picky Eating Score  
(minimum: 0 maximum: 15) 
161 (100) 4 (2–7)ab 18.5 < 0.001 
 
Poor Appetite Score 
(minimum: 0 maximum: 15) 
161 (100) 3 (0–6)a   
 
Fear of Negative Consequences Score 
(minimum: 0 maximum: 15) 
161 (100) 5 (3–9)b   
IBD Type     
Crohn’s disease 73 (45.3) 11.5 (7–19) 0.013 0.994 
Ulcerative colitis 83 (51.6) 13 (7–20)   
IBD-unclassified 5 (3.1) 11 (9–15)   
Flare Status     
No Recent Flare 110 (68.3) 12 (6.25–17) 5.212 0.074 
Recent Flare within 60 Days 11 (6.8) 10 (8–15)   
Active Flare 40 (24.8) 18.5 (8.75–26)   
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TABLE 3 (cont). Comparison of Avoidant/Restrictive Food Intake Disorder (ARFID) Risk Score 









Gender     
Female 88 (54.7) 14.5 (9–20) 3.623 0.057 
Male 73 (45.3) 11 (6–18)   
Makes Dietary Choices Based in Cultural 
Practices 
    
Yes 22 (13.7) 18 (9-26) 3.874 0.49 
No 139 (86.3) 12 (7-19)   
Avoids Food During Flare     
Yes 148 (91.9) 13 (8–20) 4.712 0.030 
No 13 (8.1) 6 (5–11)   
Avoids Food in Absence of Flare     
Yes 119 (73.9) 15 (9–20) 12.405 < 0.001 
No 42 (26.1) 8 (5–12.75)   
Kruskal-Wallis test was used to test for differences in ARFID risk score across clinical characteristics and across 
domains. 
abValues without a common superscript are significantly different as determined by Mann-Whitney U test and 




The third aim of the study was to determine the relationship between ARFID risk and 
nutritional status. The PG-SGA questionnaire was completed by 133 participants and 
nutritional risk was quantified. Twenty-nine percent of participants scored ≥ 6. The 
median nutritional risk score was 2 (IQR 1–6) (Table 4). Results indicated a positive 
linear relationship (rs(131) = 0.196, P = 0.024) between ARFID risk score and PG-SGA 
score, indicating that participants who scored higher for ARFID risk also scored higher 
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for nutritional status risk (Table 4).  BMI was inversely correlated to ARFID risk score 
(rs(159) = -0.161, P < 0.042); participants with a lower BMI score had a significantly 
higher ARFID risk score (Table 4). Percent weight loss (median = 0, IQR -1.8–0.91) did 
not differ based on IBD type (P = 0.549) or flare status (P = 0.062) and there was no 
correlation between ARFID risk score and percent weight loss (rs(153) = 0.081, P = 
0.821) (Table 4).  
TABLE 4. Correlation of Avoidant/Restrictive Food Intake Disorder (ARFID) Risk Score to Measures 
of Nutritional Status 
 
 Sample Size Median (IQR) Rho P 
Overall Nutritional Risk Score 
(minimum: 0 maximum: 36)  133 2 (1–6) 0.196 0.024 
BMI 161 23.8 (21.6–27.1) -0.161 0.042 
Percent Weight Loss  154 0 (-1.8–0.91) 0.018 0.821 
Intake Score  
(minimum: 0 maximum: 4) 133 1 (0–1) 0.039 0.654 
Spearman’s Rho was used to measure correlation between ARFID risk score and measures of 
nutritional status.  
 
Discussion 
The primary aim of this study was to describe the prevalence of ARFID risk, a 
feeding disorder characterized by avoidant and/or restrictive eating behaviors in an 
outpatient IBD population in Southern California. This study found that 17% of IBD 
patients were at risk for ARFID, specifically, 16.4% of CD patients and 19.3% of UC 
patients were at ARFID risk. No difference in ARFID risk was found between type of 
IBD, sex, or flare status. In the general gastrointestinal disorder population, ARFID risk 
has been reported between 12–21%.11,12 ARFID is associated with co-occurring anxiety 
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disorders, gastrointestinal complications, and malnutrition and proper diagnosis can help 
direct treatment and prevent nutritional and psychological complications.22 This was the 
first cross-sectional study to look at the prevalence of ARFID risk in an IBD specific 
population using a validated questionnaire. In line with previous research in the 
gastrointestinal population8 and because the Nine-Item ARFID Screen has not previously 
been used in the IBD population, a cutoff of 24 was selected for this study; however, in a 
population selected for eating disturbances, researchers found that a score of 28 was 
necessary to achieve adequate sensitivity and specificity.16 Future validation in the IBD 
population would improve the utility of the screener in clinical practice. 
Results show that 92% of IBD patients avoid foods when they are having a flare 
compared to 74% who avoid foods in the absence of a flare. Cross-sectional studies have 
found that between 49–90% of IBD patients avoid or restrict foods.3-5 This avoidance is 
likely due to patient beliefs that certain foods exacerbate IBD symptoms.23,24 One-half of 
our participants reported a nutrition impact symptom. The participants who reported that 
at least one of the symptoms—diarrhea, pain, no appetite, or fullness—prevented them 
from eating normally in the prior two weeks, were significantly more likely to have an 
ARFID risk score of 24 or higher compared to those who did not. Previous research has 
shown that IBD symptoms impact dietary intake5; however, this is the first study to draw 
associations between IBD symptoms and ARFID risk score. Of the variables included in 
the multilinear regression analysis, prior biologic use was the only clinical characteristic 
that was associated with higher ARFID risk score. It is possible that the sample size in 
this study was not large enough to detect a significant impact of the other variables that 
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were included in the model. Although the majority of IBD patients are demonstrating 
food avoidance, there is no evidence-based guideline recommending the avoidance of any 
specific food to prevent or treat IBD flares.25 Based on clinical experience, the European 
Society for Clinical Nutrition and Metabolism (ESPEN) guideline development group 
agreed that all IBD patients should be regularly screened for malnutrition and 
micronutrient deficiencies and that impairments should be corrected individually when 
necessary.25 Evidence supports the monitoring and supplementation of serum calcium and 
vitamin D levels for IBD patients in active disease and/or on steroid-treatments to help 
prevent low bone mineral density.25 For UC patients in remission, there is also evidence 
to support the use of probiotic therapy for the maintenance of remission; however, 
probiotic therapy should not be used for maintenance of remission in CD.25 There was a 
strong consensus, based on the clinical expertise of the ESPEN guideline group, that all 
IBD patients in remission should undergo counseling by a dietitian to improve nutritional 
therapy and to avoid malnutrition and nutrition-related disorders; although, the Academy 
of Nutrition and Dietetics could not draw conclusions about the optimal frequency, 
duration of nutrition professional visits, or medical nutrition therapy effectiveness for 
gastrointestinal disorders.26  
In the absence of strong evidence, the Academy of Nutrition and Dietetics Nutrition 
Care Manual (NCM) offers some guidance to practicing clinicians, advising that the 
primary goals of nutrition intervention should be to identify impediments to adequate oral 
intake, correct or compensate for malabsorption, and meet increased nutritional 
requirements, while correcting for nutritional deficiencies and losses.27 The NCM 
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recommends IBD patients in active disease eat small, frequent meals that are low in fat 
and fiber and high in protein and calories, and IBD patients in disease remission should 
prioritize weight management and nutrient intake while making individualized 
adjustments for gastrointestinal function.28 In a clinical practice expert review on the 
treatment of functional gastrointestinal symptoms in patients with IBD, Colombel et al.29 
endorse the implementation of a diet low in fermentable oligo-, di-, mono-saccharides 
and polyols (FODMAP) for IBD patients in remission. The recommendation specifies 
that because undernutrition is common in the IBD population and the low FODMAP diet 
is restrictive, it should be introduced and monitored by a dietitian with special attention 
placed on the provision of nutritional adequacy.29 This type of dietary management 
requires the expertise of medical professionals to address patient-specific intolerances 
while mitigating the risk of energy and nutrient deficiencies.  
Due to the prevalence of malnutrition in the IBD population13,14 and the self-reported 
evidence that IBD patients avoid or restrict foods in their diets3-5, this study sought to 
investigate whether ARFID was relevant in the IBD population and if it was associated 
with risk for compromised nutritional status. Malnutrition in IBD patients increases the 
risk of non-elective surgery, increased length of stay, and mortality.25 Because 
malnutrition is challenging to measure, this study investigated multiple markers of 
nutritional status including weight status, percent weight loss, and the PG-SGA 
malnutrition screener. One-third of the IBD patients in this study were found to be at risk 
of malnutrition which aligns with previous reported prevalence rates of 29–68%.6,13,14 
Unique to this study, higher ARFID risk was associated with higher malnutrition risk and 
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lower BMI status; although, only 6% of patients had a BMI low enough to be categorized 
as underweight and there was no association with recent weight loss and ARFID risk 
score. This study did not evaluate all six characteristics that can be used to diagnose 
malnutrition.30 Future studies should include a nutrition focused physical exam to 
determine loss of muscle mass, subcutaneous fat, and fluid accumulation that may mask 
malnutrition.31  
Regardless of flare status, participants reported that they avoid lactose containing 
foods, wheat products, meat, and vegetables, supporting avoidant dietary intake patterns 
that have been identified in previous studies.32,33 Common nutritional deficiencies in IBD 
patients that have been associated with food avoidance include vitamin D, calcium, iron, 
zinc, vitamin B6, vitamin B12, and vitamin C.32,33 Foods that are avoided by IBD patients 
such as dairy, meat, and raw fruits and vegetables are good sources of these essential 
nutrients and patients who avoid these foods may be at an increased risk for nutrient 
deficiencies.34 Nutrient deficiencies have been associated with increased risk of 
osteoporosis, surgery, and hospitalization.35,36 In this study, dietary assessments were not 
collected, thus the nutrient intake and adequacy of participants could not be determined.  
The majority of participants in this study avoid one or more foods during a flare or in 
remission. Our findings also show that IBD patients who report avoiding foods, whether 
in a flare or in the absence of a flare, have significantly higher ARFID risk scores 
compared to those who do not avoid foods. This indicates that IBD patient care should 
include discussion about food avoidance and ARFID risk assessment. If a patient avoids 
entire food groups, such as dairy, they should be referred to a registered dietitian as diet 
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counseling has been shown to have an impact on the nutritional status of IBD patients37 
and is recommended by the European Society for Clinical Nutrition and Metabolism.25 It 
is well established that registered dietitian nutritionists are critical to the nutrition care of 
individuals with eating disorders39 as they can perform nutrition focused physical 
examinations, assess biochemical results, and interpret weight status, implementing 
clinical judgement to direct interventions and mitigate impairments. According to 
registered dietitians, Scarlata et al.40 in the irritable bowel syndrome population, 
restrictive dietary interventions, such as the low FODMAP diet, are not universally 
appropriate and are particularly risky for patients who are at risk for eating disorders. 
They suggest that irritable bowel syndrome patients should be screened for eating 
disorders and that patients who have maladaptive food avoidance would benefit from 
coordinated care between registered dietitians and mental health providers. The results 
from this study that demonstrate the prevalence of ARFID risk in the IBD population 
show that maladaptive food avoidance is relevant and that the clinical practice 
recommendation from Scarlata et al.40 is applicable to IBD patients as well. While this 
may be time and resource intensive, individualization of dietary interventions is required 
to ensure their appropriateness, minimize nutritional risk, improve disease outcomes, and 
reduce the likelihood that maladaptive eating patterns and the associated risks are 
exacerbated. 
In the future, researchers should confirm the prevalence of ARFID in the IBD 
population through clinical verification, assessing participants psychosocial impairment 
such as work or school interference, social interference, and family interference as well 
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as medical consequences such as ARFID related weight loss, reliance on supplemental 
feeding, and ARFID related nutritional deficiency.9 There is also a need for controlled, 
prospective studies to evaluate how ARFID impacts nutritional status or deficiencies. 
Finally, evidence-based practices for the treatment of ARFID should also be established 
through rigorous clinical trials.  
In conclusion, this study establishes that IBD patients are at risk for ARFID and that 
there is an association between ARFID risk and nutritional status. With this knowledge, 
IBD patients should be screened for factors that were found to be associated with higher 
ARFID risk score such as avoidant eating behaviors, low BMI, IBD symptoms like 
diarrhea, pain, lack of appetite, and early satiety, and prior biologic treatment. Regular 
ARFID screening of IBD patients would help direct appropriate dietary interventions for 
disease and symptom management and could help identify early malnutrition risk, 
leading to earlier intervention and reduced negative outcomes.  
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Summary and Recommendations 
Summary 
Previous research has explored the relationship between diet, inflammatory bowel 
disease (IBD) etiology, and disease course; however, strong evidence-based practices for 
IBD prevention or disease management are limited due to inconsistent, poor-quality 
research (Forbes et al., 2017). As explored in chapter one, it is challenging to draw 
generalizable conclusions about the impact of diet on IBD from studies that implement 
inconsistent dietary assessment methodologies and observational study designs. Based on 
the lack of high-quality research, experts do not endorse the universal application of one 
diet pattern or the elimination of any specific foods for IBD prevention or management 
(Forbes et al., 2017); however, previous research and this study demonstrate that IBD 
patients do avoid or restrict foods (Limdi et al., 2016; Zallot et al., 2013). While avoidant 
or restrictive dietary behaviors may be effective and safe for the symptom management 
of some IBD patients, they could also increase their risk of malnutrition and/or nutrient 
deficiency. It is also possible that avoidant eating behaviors could indicate or portend the 
development of the feeding disorder avoidant/restrictive food intake disorder (ARFID), 
making the recommendation of a restrictive diet like the low fermentable oligo-, di-, 
mono-saccharides and polyols (FODMAP) diet, specific carbohydrate diet, or the anti-
inflammatory diet inappropriate.  
This study aimed to describe the prevalence of ARFID risk, identify risk factors for 
ARFID risk, and evaluate the relationship between ARFID risk and nutritional status in 
	 62	
the IBD population. While this study could not diagnose ARFID, it was the first study to 
demonstrate that a proportion of the IBD population is at risk for ARFID, with 17% of 
the 161 participants scoring equal to or above the cutoff value on the Nine-Item ARFID 
Screener instrument. Low body mass index (BMI), food avoidance regardless of disease 
status, and prior biologic treatment were identified as possible ARFID risk factors based 
on their association with higher ARFID risk scores. Participants who reported a 
nutritional impact symptom of diarrhea, pain, no appetite, or feeling full quickly were 
also significantly more likely to be at risk for ARFID. While these results do not 
demonstrate the direction of the relationship between IBD symptoms and ARFID risk, 
they do suggest a possible bi-lateral relationship between disease symptoms and 
restrictive eating behaviors. This was the first study to investigate the relationship 
between ARFID risk and nutritional status, finding that a higher ARFID risk score was 
associated with a higher malnutrition risk score. 
Recommendations 
The prevalence of ARFID risk in the IBD population and its association with 
increased nutritional risk, supports the recommendation that patients with IBD should be 
automatically referred to registered dietitians. Regular malnutrition screenings for the 
IBD population have been recommended elsewhere (Forbes et al., 2017) and this study 
augments that recommendation, proposing that if there is evidence that a patient has 
avoidant eating behaviors, the adequacy of their nutritional intake should be monitored 
closely. Implementing regular ARFID screenings in clinical practice could help 
practitioners easily identify patients with avoidant eating behavior and also help direct the 
	 63	
most appropriate nutrition interventions from registered dietitians. Patients who 
demonstrate avoidant eating behaviors may not be appropriate candidates for highly 
restrictive dietary interventions as a highly restrictive diet could exacerbate avoidant 
behaviors, leading to further food avoidance and increasing the risk for inadequate 
nutritional provision, nutrient deficiencies, and/or malnutrition.  
Due to the novelty of this area of research, there are many outstanding research 
questions. First future research should confirm the prevalence of ARFID in the IBD 
population through clinical verification, assessing psychosocial impairments and medical 
consequences. There is also a need for controlled, prospective studies to evaluate how 
ARFID diagnosis or risk impacts the nutritional status or specific nutrient deficiencies of 
IBD patients. Finally, further research is necessary to establish strong evidence-based 
guidelines for when it is appropriate to implement restrictive diets in the IBD population 
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